United global response to US childhood vaccine overhaul
International health authorities have launched a staunch defence of childhood immunisation, following a recent upheaval in the US that could…
13 Aug 2026
Akeso secures China NMPA authorisation for ivonescimab combo
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small…
13 Aug 2026
Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits
Eli Lilly has initiated a crackdown to curb the trade of illicit forms of its investigational weight loss therapy, retatrutide, as around one in five patients turn to non-vetted sellers…
13 Aug 2026
Remepy secures $36m funding for hybrid drug pipeline expansion
Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline. The proceeds will also be used to fund Remepy’s…
12 Aug 2026
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
A patient who developed multidrug-resistant E. coli following a transplant has recovered following treatment with an investigational clustered regularly interspaced short palindromic repeats (CRISPR) gene therapy. The 65-year-old kidney transplant…
12 Aug 2026
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs
Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the round, Infinimmune garnered the interest of several major industry…
12 Aug 2026
Epicrispr, Vaderis secure pivotal study funding for rare disease assets
Two biotech companies, Epicrispr Biotechnologies and Vaderis Therapeutics, have secured fresh capital to take their rare disease assets to late-stage trials – potentially poising these drugs to become the first…